Schedule M of the Drugs and Cosmetics Act outlines quality standards for pharmaceutical products.
This February, the ministry issued a notification extending the deadline for implementing revised Schedule M, whereby manufacturers with revenues of less than ₹250 crore were required to submit applications to the Central License Approving Authority within three months, along with their upgradation plans.
“However, as per the data available, very few firms have submitted their application requesting extension of timelines for implementation of revised Schedule M,” said the health secretary in her letter to states.
